Zy Therapeutics to Attend AAN 2026 in Chicago
Zy Therapeutics is pleased to announce its participation in the American Academy of Neurology (AAN) Annual Meeting 2026 in Chicago, one of the leading global forums for advances in neurological…
Zy Therapeutics to Attend International Conference on TSC and Neurocutaneous Disorders in Warsaw
Zy Therapeutics is pleased to announce its participation in the International Conference on Tuberous Sclerosis Complex and Related Neurocutaneous Disorders, taking place May 21–23, 2026 in Warsaw, Poland. This meeting…
Building Strategic Partnerships at AES 2025
As Zy Therapeutics prepares for the 2025 American Epilepsy Society (AES) Annual Meeting, the company is placing a strong emphasis on building the strategic relationships needed to advance its rare-epilepsy…
Zy Therapeutics to Highlight Kamini’s Clinical and Regulatory Progress at AES 2025
Zy Therapeutics is gearing up for an important presence at the 2025 American Epilepsy Society (AES) Annual Meeting, where the company will highlight meaningful progress on Kamini® (ZY-001)—its lead investigational…
Zy Therapeutics to Convene Scientific Advisory Board Meeting at AES 2025
Zy Therapeutics will convene its 2025 Scientific Advisory Board (SAB) meeting during the American Epilepsy Society (AES) Annual Meeting on Friday, December 5, 2025, in Atlanta, Georgia. This Scientific Advisory…
ZY Therapeutics develops Kamini for brain calcification in rare CNS diseases
Brain calcification is more than a radiographic finding, it’s a devastating driver of seizures, migraines, and cognitive decline in rare CNS diseases like Sturge-Weber Syndrome and Tuberous Sclerosis. At ZY…
Zy Therapeutics Shares New Data at ASENT 2024
Zy Therapeutics is presenting new research findings at the American Society for Experimental Neurotherapeutics (ASENT) annual meeting, taking place in Bethesda, MD, from March 12–14, 2024. The team looks forward…